secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001108205-24-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q4 2023 net loss $11.7M ($2.03/sh); cash $56.3M, clinical data from ASH shows CRs
--------------------------------------------------------------------------------

- Net loss for Q4 2023 was $11.7M ($2.03/share) vs $11.3M ($2.35/share) in Q4 2022.
- Revenue from Erivedge royalties was $2.7M for Q4 2023, flat YoY.
- Cash & investments totaled $56.3M at Dec 31, 2023; company expects runway into 2025.
- At ASH, emavusertib + ibrutinib achieved CR in 3 of 5 evaluable R/R PCNSL patients after BTKi failure.
- Updated TakeAim Leukemia data expected H1 2024; lymphoma combo and triplet combo data in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/0001108205-24-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/cris-20240208.htm
  HTML page:      https://secwatch.observer/filing/0001108205-24-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer